Advertisement
      Back to Category        

Teva and Lonza Partner on Biosimilars

By Staff


3/18/2009

US Pharm. 2009;34(3):36. 

Identifying biosimilars as a major growth driver, Israel-based Teva Pharmaceutical Industries Ltd. has established a joint venture with Switzerland-based Lonza Group Ltd. to develop, manufacture, and market a portfolio of selected biologic pharmaceuticals. The new venture is expected to begin activities during the first quarter of 2009, subject to receipt of any applicable regulatory approvals. Financial details of this agreement are not being disclosed.
Advertisement